Demonstrated strong safety and favorable pharmacokinetics in Phase 1 study A First-in-class oral small molecule modulating immune cell metabolism via glycogen phosphorylase inhibition Once-daily oral ...
Pilatus Biosciences Announces First Patient Dosed in Phase 1 Trial of First-in-Class Metabolic Checkpoint Antibody PLT012 in Solid Tumors - First-in-human study underway evaluating anti-CD36 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results